← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Torralva Medical Therapeutics, Llc
Portland, OR
$1,768,520
Total funding
2
Grants
Funding over time
peak $546.8K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,768,520 · 2
By mechanism
R44$1,393,884 · 1
R41$374,636 · 1
Investigators at Torralva Medical Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.$522,934
R44 · FY2024 · DA
Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.$446,782
R44 · FY2025 · DA
Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.$324,196
R44 · FY2022 · DA
Development of therapeutics to treat fentanyl overdose using a validated animal model$319,676
R41 · FY2021 · DA
Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.$99,972
R44 · FY2025 · DA
I-Corps Project plan for:STTR Phase I Development of therapeutics to treat fentanyl overdose using a validated animal model$54,960
R41 · FY2022 · DA